Neurogene (Neurogene) ROCE % : -35.33% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neurogene's annualized ROCE % for the quarter that ended in Mar. 2024 was -35.33%.

Neurogene ROCE % Historical Data

The historical data trend for Neurogene's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene ROCE % Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-55.74

-57.12

-24.03

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial			-47.79	-60.07	-81.22	-	-35.33

Neurogene ROCE % Calculation

Neurogene's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.305	/	( ( (109.265 - 6.651)	+	(222.573 - 22.973) )	/ 2 )
	=	-36.305	/	( (102.614	+	199.6)	/ 2 )
	=	-36.305	/	151.107
	=	-24.03 %

Neurogene's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-67.672	/	( ( (222.573 - 22.973)	+	(195.35 - 11.818) )	/ 2 )
	=	-67.672	/	( ( 199.6	+	183.532 )	/ 2 )
	=	-67.672	/	191.566
	=	-35.33 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Neurogene (NAS:NGNE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neurogene ROCE % Related Terms

Thank you for viewing the detailed overview of Neurogene's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene (Neurogene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023